Trial reportJournal of neuro-oncology2007
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
Trial report in Journal of neuro-oncology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00006358 (Phase II Evaluation of Temozolomide), which is not on this map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Evaluation of Temozolomide (SCH52365) and Thalidomide for the Treatment of Recurrent and Progressive Glioblastoma Multiforme
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Receptor tyrosine kinase targeted therapies in glioblastoma: a systematic review.Frontiers in medicine · 2026Pooled it
- The role of targeted therapies in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.Journal of neuro-oncology · 2014Guideline
- Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.Neuro-oncology · 2014Pooled it
- A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806).Journal of neuro-oncology · 2013Trial
- A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma.Journal of neuro-oncology · 2012Trial
- A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas.Journal of neuro-oncology · 2012Trial
- Trial
- A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.Journal of neuro-oncology · 2008Trial
- Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.Neuro-oncology · 2008Trial
- Claudins proteins in brain tumors: expression patterns and therapeutic target.Biochemia medica · 2026Review
- A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials.Cancers · 2021Review
- Targeting Subventricular Zone Progenitor Cells with Intraventricular Liposomal Encapsulated Cytarabine in Patients with Secondary Glioblastoma : A Report of Two Cases.SN comprehensive clinical medicine · 2020Article
- Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.Neuro-oncology · 2019Article
- Article
- A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma.Nature neuroscience · 2017Article
- The role of bevacizumab in the treatment of glioblastoma.Journal of neuro-oncology · 2017Review
- CNS Anticancer Drug Discovery and Development Conference White Paper.Neuro-oncology · 2015Article
- Impact of imaging measurements on response assessment in glioblastoma clinical trials.Neuro-oncology · 2014Article
- Targeted therapy in gliomas.Current oncology reports · 2014Review
- Blood-based biomarkers for malignant gliomas.Journal of neuro-oncology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundLaboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM).
objectivesTo determine 6-month progression-free survival (6PFS) and toxicity of temozolomide plus thalidomide in adults with recurrent GBM. PATIENTS AND
methodsEligible patients had recurrent GBM after surgery, radiotherapy, and/or adjuvant chemotherapy. Temozolomide was given at 150-200 mg/m(2)/day on days 1-5 of each 28-day cycle. Thalidomide was given orally at 400 mg at bedtime (days 1-28) and increased to 1,200 mg as tolerated. Patients were evaluated with magnetic resonance imaging scans every 56 days. The study was designed to detect an increase of the historical 6PFS for GBM from 10 to 30%.
resultsForty-four patients were enrolled, 43 were evaluable for efficacy and safety. The study population included 15 women, 29 men; median age was 53 years (range 32-84); median Karnofsky performance status was 80% (range 60-100%). Thirty-six (82%) patients were chemotherapy-naïve. There were 57 reports of toxicity of grade 3 or greater. Non-fatal grade 3-4 granulocytopenia occurred in 15 patients (34%). The objective response rate was 7%. The estimated probability of being progression-free at 6 months with this therapy is 24% [95% confidence interval (C.I.) 12-38%]. The median time to progression is 15 weeks (95% C.I. 10-20 weeks). There was no observed correlation between serum levels of vascular endothelial growth factor, basic fibroblast growth factor, and IL-8 and the 6PFS outcome.
conclusionThis drug combination was reasonably safe, but with little indication of improvement compared to temozolomide alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.